Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aldeyra TherapeuticsALDX 30 Net Cash per Share is $0.59 as of Jun. 2026, which is 82% below its 10-year median of 3.24. GuruFocus rates ALDX with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 796 Biotechnology companies, Aldeyra Therapeutics ranks better than 73.74% on this metric.
Aldeyra Therapeutics (NAS:ALDX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Aldeyra Therapeutics Net Cash per Share Related Terms
Aldeyra Therapeutics Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Aldeyra Therapeutics's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ALDX vs NTHI, BMEA, PTHS: Net Cash per Share Comparison
For the Biotechnology subindustry, Aldeyra Therapeutics's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aldeyra Therapeutics Price-to-Net-Cash vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aldeyra Therapeutics's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Aldeyra Therapeutics's Price-to-Net-Cash falls into.
Aldeyra Therapeutics Net Cash per Share Calculation
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Aldeyra Therapeutics's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aldeyra Therapeutics (ALDX) has a Net Cash per Share of $0.59 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Aldeyra Therapeutics and its competitors. This is 82% below median its historical median of 3.24. Over the past decade, Aldeyra Therapeutics' Net Cash per Share has ranged from 1.15 to 10.87. According to the industry distribution chart, Aldeyra Therapeutics ranks #209 out of 796 companies in the Biotechnology industry, placing it in the top 26.3%.
Is Aldeyra Therapeutics' Net Cash per Share too high?
Aldeyra Therapeutics' current Net Cash per Share of $0.59 is 82% below median its 10-year median of 3.24. Over the past 10 years, this metric has ranged from a low of 1.15 to a high of 10.87. The Biotechnology industry median Net Cash per Share is 5.20. Aldeyra Therapeutics' value of $0.59 is 88.7% below this industry median. Based on the distribution chart, Aldeyra Therapeutics ranks #209 out of 796 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Aldeyra Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Aldeyra Therapeutics' Net Cash per Share compare to NTHI and BMEA?
According to the Biotechnology industry distribution chart, Aldeyra Therapeutics ranks #209 out of 796 companies for Net Cash per Share. This puts Aldeyra Therapeutics in the upper half of its industry. The industry median Net Cash per Share is 5.20. Aldeyra Therapeutics' value of $0.59 is 88.7% below this benchmark. Historically, Aldeyra Therapeutics' own Net Cash per Share has ranged from 1.15 to 10.87 over the past decade. While the company's 10-year median is 3.24 vs. the industry median of 5.20, Aldeyra Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Biotechnology company?
The median Net Cash per Share among Biotechnology companies is 5.20, based on 796 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aldeyra Therapeutics's current Net Cash per Share of $0.59 is 88.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Aldeyra Therapeutics and its competitors. For the Biotechnology industry, the median Net Cash per Share is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aldeyra Therapeutics's current Net Cash per Share is $0.59, which is 82% below median its own 10-year median of 3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aldeyra Therapeutics stock overvalued right now?
Aldeyra Therapeutics (ALDX) has a current Net Cash per Share of $0.59. The current Net Cash per Share is $0.59, which is 82% below median its 10-year median of 3.24 and 88.7% below the Biotechnology industry median of 5.20. Aldeyra Therapeutics' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Aldeyra Therapeutics (ALDX), the current Net Cash per Share is $0.59 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
30GF Score
Get the complete analysis for ALDX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALDX has been successfully added to your 
